ArticleJournal of medical physics
Is there Any Impact of Tumor Volume in Stereotactic Body Radiation Therapy for Lung Cancer? A Cohort for T1, 2 Non-small Cell Lung Cancer Cases.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/Aim: The aim of the study was to assess the impact of tumor size on dose-volume histograms (DVHs) and clinical outcomes in patients with early-stage non-small cell lung cancer (NSCLC) undergoing stereotactic body radiation therapy (SBRT) using the CyberKnife M6 System with a lung-optimized treatment module. Materials and Methods: Retrospective analysis was performed on 12 patients diagnosed with NSCLC receiving SBRT treatment. Analysis of cumulative DVHs was done to evaluate dose distribution in the planning target volume (PTV) and surrounding organs at risk. The patient population was divided according to tumor size; one group was patients with PTV <12 cc and the other group was patients with PTV >12 cc. Statistical analysis was performed using SPSS software. Results: All treatment plans achieved adequate target coverage with sharp dose gradients. There was slight improvement in terms of dose distribution and response rate for smaller tumors (PTV <12 cc); however, these differences did not show statistical significance. Conclusions: There were no statistically significant differences between tumor volume and DVH parameters or clinical response in SBRT treatment of NSCLC. Most of the patients received biological effective dose (α/β =10) values above 100 Gy, with some of them receiving >120 Gy, which has been associated with improved treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.